Abstract
Multikinase inhibitors are effective treatments for thyroid cancers, acting primarily as antiangiogenic agents. This year, advances have been made in selective targeting of RET and BRAF in patients with medullary and anaplastic thyroid cancers, respectively. However, Hürthle cell carcinomas have a unique genomic landscape with no dominant truncal drivers, precluding simplistic approaches to therapeutic targeting.
Publication types
-
Research Support, N.I.H., Extramural
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / administration & dosage*
-
Carcinoma, Papillary / drug therapy*
-
Carcinoma, Papillary / metabolism
-
Humans
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / metabolism
-
Proto-Oncogene Proteins c-ret / antagonists & inhibitors*
-
Proto-Oncogene Proteins c-ret / metabolism
-
Pyrazoles / administration & dosage
-
Pyridines / administration & dosage
-
Pyrimidines / administration & dosage
-
Thyroid Neoplasms / drug therapy*
-
Thyroid Neoplasms / metabolism
Substances
-
Antineoplastic Agents
-
Pyrazoles
-
Pyridines
-
Pyrimidines
-
pralsetinib
-
selpercatinib
-
Proto-Oncogene Proteins c-ret
-
RET protein, human
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf